NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/12/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,017.26 mln
Float217 mln
Earnings Date10/29/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.23
Borderline
Relative Strength
4
/ 100
Severely lagging
Debt / Equity
1.40
Elevated leverage
ROE
-38.45
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Ardelyx is a pharmaceutical company based in Waltham, Massachusetts, that creates and sells treatments for conditions that have few or no existing solutions, both in the United States and abroad. Its two main products are IBSRELA, used to treat irritable bowel syndrome with constipation, and XPHOZAH, which helps control phosphorus levels in adults with chronic kidney disease who are on dialysis. Founded in 2007 under the name Nteryx, the company rebranded as Ardelyx in 2008.
